Cellular Health Market Leader Tru Niagen® Launches Online in Australia
March 23 2020 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce launch
of Tru Niagen® in Australia with distribution partner Matakana
Health Limited (MHL). Tru Niagen received its listing number on the
Australian Registry of Therapeutic Goods (ARTG) on January 8, 2020
(AUST L 328365). Tru Niagen is a breakthrough supplement to
increase NAD+ (nicotinamide adenine dinucleotide) levels, help
maintain general health and well-being, and support energy levels.
“When our bodies face physiological stress, it is more important
than ever that we maintain NAD+ levels to support tissue repair and
general health and well-being,” says Dr. Andrew Shao, ChromaDex SVP
of Global Scientific & Regulatory Affairs. “Boosting NAD+ will
also help maintain energy levels to keep up with fitness routines
while at home.”
NAD+ levels decline with age. Maintaining healthy NAD+ levels
becomes increasingly important to support one’s general health as
they get older. Tru Niagen effectively boosts NAD+ levels safely as
demonstrated in six published human trials.
“I encourage everyone to stay active, healthy, and fit during
this dynamic period around the world,” says Australian Olympic
medalist and world champion swimmer James Magnussen, who is a Tru
Niagen user and spokesperson. “Whether that means taking solo runs
outside or watching fitness classes on your television, there are
always ways to stay on top of your health in addition to
maintaining a healthy diet.”
ChromaDex partnered with Matakana Health to launch Tru Niagen®
in New Zealand in September 2018 and recently expanded the
partnership to include distribution rights in Australia.
“Maintenance of NAD+ levels is fundamental to human health and
well-being,” says Matakana Health CEO Kevin Glucina. “We appreciate
the robust science behind Tru Niagen and are happy to launch this
product in Australia with the pioneers at ChromaDex.”
MHL is an established dietary supplement manufacturer and
distributor in New Zealand with national and Australian
distribution in both online and offline channels. The company has
more than 90 lines of organic and superfood products.
In December 2019, ChromaDex's patented nicotinamide riboside
chloride (NR) was listed in the Therapeutic Goods (Permissible
Ingredients) Determination for use in listed complementary
medicines.
For additional information on Tru Niagen, please visit
www.truniagen.com.au.
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside
chloride, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. ChromaDex maintains a website at www.chromadex.com to
which ChromaDex regularly posts copies of its press releases as
well as additional and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. Such
statements include the quotation from ChromaDex’s SVP of Global
Scientific & Regulatory Affairs. More detailed information
about ChromaDex and the risk factors that may affect the
realization of forward-looking statements is set forth in
ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2019, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Senior
Director of Global Corporate Communications310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Vice President of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2024 to Oct 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Oct 2023 to Oct 2024